12 hours Ago
Taysha Gene Therapies, Inc. ( NASDAQ: TSHA ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director and Head, Investor Relations Sean Nolan - Chief Executive Officer Sukumar Nagendran - President and Head, R&D Kamran Alam - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Chris Raymond - Piper Sandler Whitney Ijem - Canaccord Genuity Salveen Richter - Goldman Sachs Gil Blum - Needham & Co. Maury Raycroft - Jefferies Jack Allen - Baird Joon Lee - Truist Securities Silvan Tuerkcan - Citizens JMP Keith Tapper - BMO Capital Markets Operator Greetings.
And welcome to the Taysha Gene Therapies’ Third Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation.
As a reminder, this conference is being recorded. [Operator Instructions] It is now my pleasure to introduce Hayleigh Collins, the Director and Head of Investor Relations. Thank you and you may proceed, Hayleigh.
Hayleigh Collins Thank you. Good afternoon. And welcome to Taysha’s third quarter 2024 financial results and corporate update conference call.
Earlier today, Taysha issued a press release announcing financial results for the third quarter ended September 30, 2024. A copy of this press release is available on the company’s website and through our SEC filings. Joining me on today’s call are Sean Nolan, Taysha’s CEO; Sukumar Nagendran, President and Head of R and Kamran Alam, Chief Financial Officer.
We will hold a question-and-answer session following our prepared remarks. Please note that on today’s call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients’ dose-to-date in clinical trials to positively impact quality of life and alter the course of disease in the patients we seek to.
